Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
BackgroundOmalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with moderate...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Allergy |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2023.1236798/full |